Thermo Fisher Scientific
Osteosarcoma is the most common type of primary bone cancer affecting adolescents and children attributed to rapid bone growth and turnover with a peak incidence at 18 years old. it is a rare incurable and often fatal disease. The current osteosarcoma treatments include standard chemotherapy, limb salvage surgery or amputation. The 5-year relative survival rate is 70% for localized forms, however, metastasis is present in about one fifth to one-quarter of patients at diagnosis, which then contributes to a 5-year survival rate of around 20%. The survival statistics have remained constant with no advances in treatment options for decades highlighting the need for new therapeutic options.
Watch Now
LabRoots Inc.
Our 6th Annual Cancer Research & Oncology Virtual Event is now available On Demand! This free online event will bring research professionals, scientists, and clinicians from around the world to learn and discuss recent advances in cancer research. As with all LabRoots events, the Cancer Research and Oncology Event encourages a worldwide collaboration and connections between colleagues and field experts.
Watch Now
Eeuropeanpharmaceuticalreview
In this webinar, we introduce you to laboratory information management systems (LIMS) and demonstrate how this software can help you achieve regulatory compliance, quality data management throughout your product’s life cycle.
Watch Now
labroots
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a given patient. In order to expeditiously evaluate a targeted agent against a potential ‘driver’ genetic aberration, so-called Basket trials are conducted.
Watch Now